GIKLY News and Press, Grifols SA Barcelona ADR From 02/28/23

Grifols, S.A. (GRFS) Q4 2022 Earnings Conference Call February 28, 2023 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Executive Chairman Victor Grifols Deu - Co-CEO Alfredo Arroyo - CFO Conference Call Participants Peter Verdult...

We are value investors. In constructing portfolios for our clients, we seek out companies that we believe are trading in the market at significant discounts to their underlying value. These businesses must offer significant profit potential and be run by managers who think and act as owne...

Grifols (NASDAQ:GRFS) unit Araclon Biotech reported results for the first part of a phase 2 trial of its vaccine ABvac40 for Alzheimer's Disease (AD) and data on two studies of its assay ABtest-MS to identify early-stage AD. The company said ABvac40 meets the main objectives on safe...

FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...

Grifols currently trading at a 30% discount to European specialty pharma. Biotest AG Investment analysis. Biotest R&D not priced in. For further details see: Grifols: Short-Term Turbulence But Long-Term Upside

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma - The new Biomat USA plasma donor center, located at UMass Chan Medical School campus in Worcester, Mass., is Grifols' first donor center in the state and secon...

Meletios Verras/iStock via Getty Images Grifols ([[GIKLY]]) says that the novel mechanism of action of subsidiary GigaGen's anti-CTLA-4 drug candidate, GIGA-564, for cancer indications leads to superior anti-tumor activity and lower toxicity in a mouse model. GigaGen says that GIGA-564 differ...

Grifols outlines some promising new initiatives and financial targets at its latest Capital Markets Day. The most notable shift this time around was the R&D/innovation focus, which should boost the longer-term growth outlook. With the valuation discount to CSL widening to unwa...

The following slide deck was published by Grifols, S.A. in conjunction with this event. For further details see: Grifols presents at 2021 investor and analyst day - slideshow